Topic: infectious disease
VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.
Protection against active pulmonary tuberculosis disease remained up around 50%, suggesting the candidate provides lasting immunity.
The goal is to start testing in vivo gene-based treatments for the diseases in humans within 10 years.
Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.
The FDA approved its first rapid in vitro diagnostic for confirming Ebola virus infections with potential results in about a half-hour.
Micro cap anti-infective biotech Aridis Pharmaceuticals has gained a new chief medical officer in the form of former Takeda Vaccines exec Paul Mendelm
The deal gives Merck the chance to pick up three assets against undisclosed diseases in return for up to $347.5 million per projects in milestones.
After poaching an ex-Merck exec to run its R&D, Chinese biotech Ascletis has raided another U.S. Big Pharma for its new chief scientific officer.
The vaccine is built on computationally designed self-assembling VLP technology that Icosavax thinks can eliminate barriers to protecting against RSV.
The FDA plans to increase the number of clinical offices and divisions and group them by therapeutic area.